{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T22:16:35Z","timestamp":1788300995302,"version":"build-2803163510"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.pupt.2026.102432","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T23:31:30Z","timestamp":1780961490000},"page":"102432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["The preclinical discovery and development of depemokimab for severe eosinophilic asthma"],"prefix":"10.1016","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4895-9707","authenticated-orcid":false,"given":"Mario","family":"Cazzola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"Patella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raffaella","family":"Pagliaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Bianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Rogliani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Gabriella","family":"Matera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pupt.2026.102432_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaci.2019.05.031","article-title":"Phenotypes and endotypes of adult asthma: moving toward precision medicine","volume":"144","author":"Kaur","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"10379","key":"10.1016\/j.pupt.2026.102432_bib2","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.pupt.2026.102432_bib3","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.3389\/fphys.2019.01514","article-title":"Interleukin-5 in the pathophysiology of severe asthma","volume":"10","author":"Pelaia","year":"2019","journal-title":"Front. Physiol."},{"issue":"3 Pt 1","key":"10.1016\/j.pupt.2026.102432_bib4","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1164\/ajrccm.156.3.9610033","article-title":"Relationship between IL-4 and IL-5 mRNA expression and disease severity in atopic asthma","volume":"156","author":"Humbert","year":"1997","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"7","key":"10.1016\/j.pupt.2026.102432_bib5","article-title":"Anti-IL-5 therapies for asthma","volume":"7","author":"Farne","year":"2022","journal-title":"Cochrane Database Syst. Rev."},{"issue":"2","key":"10.1016\/j.pupt.2026.102432_bib6","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJMra2032506","article-title":"Biologic therapies for severe asthma","volume":"386","author":"Brusselle","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pupt.2026.102432_bib7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-world effectiveness of benralizumab in severe eosinophilic asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.pupt.2026.102432_bib8","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/02770903.2024.2449229","article-title":"Real-world effectiveness of mepolizumab in asthma: a systematic review and meta-analysis","volume":"62","author":"Di Bona","year":"2025","journal-title":"J. Asthma"},{"issue":"5","key":"10.1016\/j.pupt.2026.102432_bib10","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.anai.2023.07.017","article-title":"Real-world severe asthma biologic administration and adherence differs by biologic: CHRONICLE study results","volume":"131","author":"Ledford","year":"2023","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"10.1016\/j.pupt.2026.102432_bib11","doi-asserted-by":"crossref","first-page":"695","DOI":"10.2147\/JAA.S522414","article-title":"The impact of biological therapies and the significance of their adherence on asthma outcomes in a single tertiary asthma center","volume":"18","author":"Al-Lehebi","year":"2025","journal-title":"J. Asthma Allergy"},{"issue":"10482","key":"10.1016\/j.pupt.2026.102432_bib12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/S0140-6736(25)00197-7","article-title":"Efficacy and safety of twice per year depemokimab in chronic rhinosinusitis with nasal polyps (ANCHOR-1 and ANCHOR-2): phase 3, randomised, double-blind, parallel trials","volume":"405","author":"Gevaert","year":"2025","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.pupt.2026.102432_bib13","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1097\/ACI.0000000000001112","article-title":"Depemokimab: a new long-acting anti-IL5 treatment for severe asthma and chronic rhinosinusitis with nasal polyps","volume":"25","author":"Bernstein","year":"2025","journal-title":"Curr. Opin. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.pupt.2026.102432_bib14","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/s41423-019-0210-8","article-title":"Orchestration between ILC2s and Th2 cells in shaping type 2 immune responses","volume":"16","author":"Gurram","year":"2019","journal-title":"Cell. Mol. Immunol."},{"issue":"10","key":"10.1016\/j.pupt.2026.102432_bib15","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1016\/j.molcel.2024.03.023","article-title":"Structure of the interleukin-5 receptor complex exemplifies the organizing principle of common beta cytokine signaling","volume":"84","author":"Caveney","year":"2024","journal-title":"Mol Cell"},{"key":"10.1016\/j.pupt.2026.102432_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.cytogfr.2019.05.003","article-title":"Synergy of interleukin (IL)-5 and IL-18 in eosinophil mediated pathogenesis of allergic diseases","volume":"47","author":"Kandikattu","year":"2019","journal-title":"Cytokine Growth Factor Rev."},{"issue":"6","key":"10.1016\/j.pupt.2026.102432_bib17","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1084\/jem.180.6.2101","article-title":"IL-5 receptor-mediated tyrosine phosphorylation of SH2\/SH3-containing proteins and activation of Bruton's tyrosine and janus 2 kinases","volume":"180","author":"Sato","year":"1994","journal-title":"J. Exp. Med."},{"issue":"6","key":"10.1016\/j.pupt.2026.102432_bib18","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1101\/gad.11.6.701","article-title":"The PI 3-kinase\/Akt signaling pathway delivers an anti-apoptotic signal","volume":"11","author":"Kennedy","year":"1997","journal-title":"Genes Dev."},{"issue":"3","key":"10.1016\/j.pupt.2026.102432_bib19","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1183\/09031936.97.10030624","article-title":"IL-5 production by bronchoalveolar lavage and peripheral blood mononuclear cells in asthma and atopy","volume":"10","author":"Tang","year":"1997","journal-title":"Eur. Respir. J."},{"issue":"12","key":"10.1016\/j.pupt.2026.102432_bib20","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s10038-005-0304-2","article-title":"Association analysis of interleukin 5 receptor alpha subunit (IL5RA) polymorphisms and asthma","volume":"50","author":"Cheong","year":"2005","journal-title":"J. Hum. Genet."},{"issue":"4","key":"10.1016\/j.pupt.2026.102432_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.3390\/cells10040817","article-title":"Regulation of eosinophilia in asthma - new therapeutic approaches for asthma treatment","volume":"10","author":"Cusack","year":"2021","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.pupt.2026.102432_bib22","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/imm.12842","article-title":"Bone marrow type 2 innate lymphoid cells: a local source of interleukin-5 in interleukin-33-driven eosinophilia","volume":"153","author":"Johansson","year":"2018","journal-title":"Immunology"},{"key":"10.1016\/j.pupt.2026.102432_bib24","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1007\/978-1-61779-974-7_13","article-title":"Humanization by CDR grafting and specificity-determining residue grafting","volume":"907","author":"Kim","year":"2012","journal-title":"Methods Mol. Biol."},{"issue":"6","key":"10.1016\/j.pupt.2026.102432_bib25","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/cts.12567","article-title":"Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development","volume":"11","author":"Ovacik","year":"2018","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.pupt.2026.102432_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.968206","article-title":"Discovery of functionally distinct anti-C7 monoclonal antibodies and stratification of anti-nicotinic AChR positive myasthenia gravis patients","volume":"13","author":"Lekova","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.pupt.2026.102432_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2025.e44247","article-title":"Generation and preclinical assessment of depemokimab, an enhanced IL-5 antagonist monoclonal antibody","volume":"12","author":"Orecchia","year":"2026","journal-title":"Heliyon"},{"issue":"33","key":"10.1016\/j.pupt.2026.102432_bib28","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.pupt.2026.102432_bib29","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"2","key":"10.1016\/j.pupt.2026.102432_bib31","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1111\/bcp.15002","article-title":"A phase 1 study of the long-acting anti-IL-5 monoclonal antibody GSK3511294 in patients with asthma","volume":"88","author":"Singh","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.pupt.2026.102432_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1002\/cpdd.1506","article-title":"Pharmacokinetics of depemokimab delivered by safety syringe device or autoinjector in healthy adults: a phase 1, single-dose study","volume":"14","author":"Schalkwijk","year":"2025","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"10.1016\/j.pupt.2026.102432_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.70183","article-title":"Straight to phase III: model-Informed approach speeds depemokimab clinical development in interleukin-5-driven diseases","author":"Zecchin","year":"2026","journal-title":"Clin. Pharmacol. Ther."},{"issue":"5","key":"10.1016\/j.pupt.2026.102432_bib34","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S2213-2600(17)30125-X","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"issue":"13","key":"10.1016\/j.pupt.2026.102432_bib35","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.pupt.2026.102432_bib36","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1056\/NEJMoa2406673","article-title":"Twice-yearly depemokimab in severe asthma with an eosinophilic phenotype","volume":"391","author":"Jackson","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"3","key":"10.1016\/j.pupt.2026.102432_bib37","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1164\/rccm.201310-1863PP","article-title":"Minimal clinically important differences in pharmacological trials","volume":"189","author":"Jones","year":"2014","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"176","key":"10.1016\/j.pupt.2026.102432_bib38","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0181-2024","article-title":"Pro: clinical remission in asthma - implications for asthma management","volume":"34","author":"Principe","year":"2025","journal-title":"Eur. Respir. Rev."},{"issue":"7","key":"10.1016\/j.pupt.2026.102432_bib39","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1164\/rccm.202311-2192OC","article-title":"Exploring definitions and predictors of severe asthma clinical remission after biologic treatment in adults","volume":"210","author":"Perez-de-Llano","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"2","key":"10.1016\/j.pupt.2026.102432_bib40","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.jaip.2025.10.011","article-title":"Long-term clinical remission on biologics: an analysis of real-world data from the UK severe asthma registry","volume":"14","author":"Redmond","year":"2026","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"8","key":"10.1016\/j.pupt.2026.102432_bib41","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.3390\/jcm12082900","article-title":"A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma","volume":"12","author":"Oishi","year":"2023","journal-title":"J. Clin. Med."},{"issue":"2","key":"10.1016\/j.pupt.2026.102432_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2025.12.831","article-title":"Long-term safety and efficacy of depemokimab in patients with type 2 asthma: a single-arm, open-label extension study (AGILE) [abstract]","volume":"157","author":"Wechsler","year":"2026","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.pupt.2026.102432_bib43","doi-asserted-by":"crossref","DOI":"10.1093\/ajrccm\/aamag031","article-title":"Switching to twice-yearly depemokimab from mepolizumab\/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE)","author":"Chupp","year":"2026","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.pupt.2026.102432_bib44","article-title":"Safety and tolerability of twice-yearly depemokimab in patients with asthma and chronic rhinosinusitis with nasal polyps: pooled results from SWIFT-1\/-2 and ANCHOR-1\/-2","author":"Jackson","year":"2025","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pupt.2026.102432_bib45","series-title":"UK Approves the First twice-yearly Biological Medicine for Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps. MHRA Press Release","year":"2025"},{"key":"10.1016\/j.pupt.2026.102432_bib46","series-title":"Exdensur (Depemokimab) Approved in Japan for Severe Asthma and Chronic Rhinosinusitis with Nasal Polyps","year":"2026"},{"key":"10.1016\/j.pupt.2026.102432_bib47","series-title":"CHMP Positive Opinion for Exdensur (Depemokimab) for the Treatment of Severe Eosinophilic Asthma and Chronic Rhinosinusitis with Nasal Polyps. EMA Press Release","year":"2025"},{"issue":"5","key":"10.1016\/j.pupt.2026.102432_bib49","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1007\/s12325-021-01687-w","article-title":"Treatment persistence and adherence among patients with psoriatic arthritis who initiated targeted immune modulators in the US: a retrospective cohort study","volume":"38","author":"Walsh","year":"2021","journal-title":"Adv. Ther."},{"key":"10.1016\/j.pupt.2026.102432_bib50","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2147\/JAA.S125948","article-title":"Late-onset asthma: current perspectives","volume":"11","author":"Hirano","year":"2018","journal-title":"J. Asthma Allergy"},{"key":"10.1016\/j.pupt.2026.102432_bib51","article-title":"Impact of mepolizumab on airway remodeling and inflammation in severe eosinophilic asthma","author":"Taill\u00e9","year":"2025","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.pupt.2026.102432_bib52","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/j.jaci.2024.10.024","article-title":"Effect of mepolizumab in airway remodeling in patients with late-onset severe asthma with an eosinophilic phenotype","volume":"155","author":"Domvri","year":"2025","journal-title":"J. Allergy Clin. Immunol."},{"issue":"5","key":"10.1016\/j.pupt.2026.102432_bib53","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/14740338.2025.2467817","article-title":"Biosimilars and immunogenicity: a matter of concern?","volume":"24","author":"Jarab","year":"2025","journal-title":"Expert Opin. Drug Saf."},{"issue":"8","key":"10.1016\/j.pupt.2026.102432_bib54","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.mayocp.2022.02.018","article-title":"Twenty years of targeted and biologic immunomodulatory drugs: postmarketing modifications of drug labels approved by the US food and drug administration","volume":"97","author":"Berman","year":"2022","journal-title":"Mayo Clin. Proc."},{"issue":"7","key":"10.1016\/j.pupt.2026.102432_bib55","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1111\/all.12169","article-title":"The consequences of not having eosinophils","volume":"68","author":"Gleich","year":"2013","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.pupt.2026.102432_bib56","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40264-020-00926-3","article-title":"Safety of eosinophil-depleting therapy for severe, eosinophilic asthma: focus on benralizumab","volume":"43","author":"Jackson","year":"2020","journal-title":"Drug Saf."},{"issue":"5","key":"10.1016\/j.pupt.2026.102432_bib57","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"issue":"8","key":"10.1016\/j.pupt.2026.102432_bib58","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1016\/j.jaip.2024.04.033","article-title":"MELTEMI and COLUMBA: 5-Year comparative safety analysis of benralizumab and mepolizumab","volume":"12","author":"Bourdin","year":"2024","journal-title":"J. Allergy Clin. Immunol. Pract."},{"issue":"1","key":"10.1016\/j.pupt.2026.102432_bib59","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2024.2417184","article-title":"Long-term safety of mepolizumab for up to \u223c10 years in patients with severe asthma: open-label extension study","volume":"56","author":"Pavord","year":"2024","journal-title":"Ann. Med."},{"issue":"10516","key":"10.1016\/j.pupt.2026.102432_bib60","doi-asserted-by":"crossref","first-page":"2282","DOI":"10.1016\/S0140-6736(25)01625-3","article-title":"Anti-cytokine biologics for asthma in adults","volume":"406","author":"Israel","year":"2025","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.pupt.2026.102432_bib61","first-page":"90","article-title":"Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals","volume":"29","author":"Xu","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"10","key":"10.1016\/j.pupt.2026.102432_bib62","doi-asserted-by":"crossref","first-page":"2662","DOI":"10.1111\/all.16303","article-title":"Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: effects on and beyond eosinophils","volume":"79","author":"Buchheit","year":"2024","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.pupt.2026.102432_bib63","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2022.05.024","article-title":"Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"150","author":"Akenroye","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"issue":"3","key":"10.1016\/j.pupt.2026.102432_bib64","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jaci.2022.11.021","article-title":"Comparative efficacy of tezepelumab to mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis","volume":"151","author":"Nopsopon","year":"2023","journal-title":"J. Allergy Clin. Immunol."}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553926000258?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553926000258?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T21:59:55Z","timestamp":1788299995000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553926000258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":60,"alternative-id":["S1094553926000258"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2026.102432","relation":{},"ISSN":["1094-5539"],"issn-type":[{"value":"1094-5539","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The preclinical discovery and development of depemokimab for severe eosinophilic asthma","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2026.102432","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102432"}}